Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company is known for its innovative approach to treating conditions like depression and migraines. In the competitive healthcare sector, Axsome stands out with its commitment to addressing unmet medical needs.
On December 4, 2025, Herriot Tabuteau, the CEO and a significant shareholder of Axsome, sold 10,558 shares of the company's common stock at $148.18 each. This transaction was officially reported on Form 4. After this sale, Tabuteau retains 7,229 shares, maintaining a vested interest in the company's future.
Axsome recently showcased its progress at the Piper Sandler 37th Annual Healthcare Conference. This event is a key gathering for industry leaders and investors, providing Axsome with a platform to highlight its latest developments. The company's participation underscores its active engagement with the healthcare community.
Currently, AXSM's stock is priced at $148.04, marking a slight increase of 0.16% from the previous session. The stock has seen fluctuations today, with a low of $147.56 and a high of $149.59. Over the past year, AXSM has experienced a range between $75.56 and $152.94, reflecting its dynamic market presence.
Axsome's market capitalization is approximately $7.46 billion, indicating its substantial size in the biopharmaceutical industry. Today's trading volume on the NASDAQ is 351,301 shares, showing active investor interest. The company's strategic moves and market performance continue to attract attention in the healthcare sector.
